Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21493114 | 0.85 | KDM5A (0.35) | — | |
| SCHEMBL4823005 | 0.80 | — | — | |
| SCHEMBL17159408 | 0.77 | TACR1 (0.34) | TACR1 | |
| SCHEMBL754086 | 0.72 | TRPA1 (0.38) | — | |
| SCHEMBL23302996 | 0.71 | IDO1 (0.44) | TACR1 | |
| SCHEMBL1244135 | 0.70 | SLC6A4 (0.35) | TACR1 | |
| SCHEMBL2415833 | 0.69 | — | — | |
| SCHEMBL1586886 | 0.69 | SMYD2 (0.33) | — | |
| SCHEMBL3411831 | 0.68 | NPC1 (0.37) | — | |
| SCHEMBL2986949 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383642-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2488500-A1 | SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES | Eli Lilly and Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110092531-A1 | Novel Spiropiperidine Compounds | ELI LILLY AND COMPANY (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011046851-A1 | SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES | ELI LILLY AND COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092531-A1 | Novel Spiropiperidine Compounds | REN, SLC5A1, SLC5A2 | S1PR1 248/4885S1PR3 318/4885TACR1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.